克唑替尼治疗非小细胞肺癌的研究  

Crizotinib in the Treatment of Non-small Cell Lung Cancer

作　　者：牙韩达 韦亚娜[1] 吴燕[1] YA Han-da;WEI Ya-na;WU Yan(Department of Oncology,Hechi People's Hospital,Hechi 547000,Guangxi,China)

机构地区：[1]广西河池市人民医院肿瘤科

出　　处：《医学信息》2019年第21期43-45,共3页Journal of Medical Information

摘　　要：非小细胞肺癌(NSCLC)是肺癌常见类型,早期诊断难度较大,5年生存率低。克唑替尼作为抑制Met/ALK/ROS的ATP竞争性的多靶点蛋白激酶抑制剂,是治疗NSCLC的分子靶向药物,在控制变性淋巴瘤激酶(ALK)阳性NSCLC患者疾病发展中具有重要意义,可有效延长患者无进展生存期,且较化疗毒副反应更小,患者耐受性高,但克唑替尼的耐药性也是临床关注重点。本文主要对克唑替尼治疗NSCLC、克唑替尼药理作用及其临床效果、耐药后治疗等进行综述,旨在为更好的发挥该药治疗效果,为临床治疗NSCLC提供参考依据。Non-small cell lung cancer(NSCLC)is a common type of lung cancer.It is difficult to diagnose early and has a 5-year survival rate.Crizotinib,a multi-target protein kinase inhibitor that inhibits ATP competition in Met/ALK/ROS,is a molecularly targeted drug for the treatment of NSCLC and is important in controlling disease progression in patients with degenerative lymphoma kinase(ALK)-positive NSCLC.Significance can effectively prolong the progression-free survival of patients,and is less toxic than chemotherapy,and patients are highly tolerant,but the resistance of crizotinib is also the focus of clinical attention.This article is mainly to review the pharmacological effects of crizotinib in the treatment of NSCLC,crizotinib and its clinical effects,treatment after drug resistance,etc.,in order to better play the therapeutic effect of this drug,and provide a reference for clinical treatment of NSCLC.

关 键 词：非小细胞肺癌 克唑替尼 作用机制 药代动力学 药理毒理 

分 类 号：R734.2[医药卫生—肿瘤]